Industry News
Biotechnology Industry News
Almost exactly one year ago, Janux…
Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike. But the biotech’s newest update has failed to garner the same investor enthusiasm, with
Tiziana Life Sciences has pointed…
Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company.
Imvax has shrugged off the failure…
Imvax has shrugged off the failure of its phase 2b brain cancer trial to hit its primary endpoint, reporting evidence of improved overall survival and making a beeline for the FDA.
The European Union has launched a…
The European Union has launched a new funding initiative to support healthcare startups across the continent. The EU’s investment arm, the European Investment Bank (EIB), is teaming up with Italian conglomerate Angelini Industries to funnel
The companies will jointly develop…
The companies will jointly develop and commercialize Tessera's TSRA-196, a near-clinic candidate for alpha-1 antitrypsin deficiency (AATD) that uses Tessera's gene writing technique.
Akebia Therapeutics has struck a…
Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease pipeline.
A phase 3 trial of Belite Bio’s…
A phase 3 trial of Belite Bio’s tinlarebant in adolescents with a rare genetic eye disease has met its primary endpoint, encouraging the biotech to add the U.S. to the list of countries where it
French vaccine maker Valneva is…
French vaccine maker Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles.
Artificial intelligence is booming…
Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines.
The FDA has delayed a decision on…
The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three months to buy time to review recently submitted information.
A federal commission is warning…
A federal commission is warning that the U.S. is losing its innovative edge, arguing that the nation needs to “reimagine the federal science enterprise” by streamlining funding and incorporating AI into processes.
Protego Biopharma will use the…
Protego Biopharma will use the funding to run pivotal studies of its amyloid light-chain amyloidosis prospect PROT-001.
AbbVie is opening up submissions…
AbbVie is opening up submissions for an award that will provide one Canadian biotech free access to lab space and executive insights from the Big Pharma.
Amid a groundswell of questions…
Amid a groundswell of questions and pushback over the FDA's Commissioner's National Priority Voucher program, two lawmakers are seeking to gain more clarity.
Novo Nordisk is hitting the gas on…
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity prospect.
A drug safety group has delivered…
A drug safety group has delivered a positive analysis for a Sarepta-licensed RNA medicine, with the same study also hitting an enrollment target. The latter development has triggered a $200 milestone payment due to Arrowhead
Swedish biotech Sprint Bioscience…
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in biobucks.
VC Versant Ventures is unveiling…
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen.
Johnson & Johnson’s attempt…
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to significantly slow clinical decline,
Bayer’s oral FXIa inhibitor…
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past two years.